Skip to main content
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. logo

MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 688062 ISIN · CNE100005RD2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 541 across all filing types
Latest filing 2024-04-08 Annual Report
Country CN China
Listing Shanghai Stock Exchange 688062

About MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.

https://www.mabwell.com/en/

Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of therapeutic antibodies and innovative biologics. The company maintains an integrated R&D and manufacturing platform covering the full drug lifecycle, from target discovery and preclinical research to clinical development and commercial production. Its therapeutic pipeline addresses critical needs in oncology, autoimmune diseases, metabolic disorders, ophthalmology, and infectious diseases. Mabwell leverages proprietary technology platforms, including antibody-drug conjugates (ADCs), bispecific antibodies, and high-throughput screening, to develop a diverse portfolio of novel drug candidates and biosimilars. The organization is committed to delivering high-quality, accessible therapeutic solutions through its end-to-end biotechnological capabilities.

Recent filings

Filing Released Lang Actions
迈威生物2023年年度报告
Annual Report Classification · 100% confidence The document is titled '2023 年年度报告' which translates to '2023 Annual Report'. It contains detailed financial data, management discussion and analysis, company overview, risk factors, financial statements, and audit report information. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. It includes signatures from company officers and auditors, detailed financial metrics, and comprehensive company information. These characteristics align with the definition of an Annual Report (10-K).
2024-04-08 Chinese
迈威生物关于召开2023年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2023 Annual General Meeting (AGM) of the company, including the date, voting methods, agenda items, and instructions for shareholders. It includes information about the meeting logistics, voting procedures, and proxy authorization. The document does not contain the actual annual report, financial statements, or detailed financial data, but rather the announcement and preparation for the AGM where such reports will be discussed and voted on. This fits the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or notices about the AGM itself. The document length is over 5,000 characters and is comprehensive about the AGM details, not just a brief announcement, so it is not a Report Publication Announcement (RPA). Therefore, the correct classification is AGM Information (AGM-R).
2024-04-08 Chinese
迈威生物2023年度内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制审计报告" which translates to "Internal Control Audit Report." It is issued by a registered accounting firm (Ernst & Young Hua Ming) and dated April 8, 2024, covering the internal control over financial reporting as of December 31, 2023. The content includes the auditor's responsibility, management's responsibility, inherent limitations of internal control, and the auditor's opinion on the effectiveness of internal control over financial reporting. This is a standalone audit report focused on internal control effectiveness, not a full annual report or financial statement. It matches the definition of an Audit Report / Information (AR) which includes standalone audit reports and applied accounting principles. The document length is over 12,000 characters, indicating it is a full report, not just an announcement or certification. Therefore, the correct classification is AR with high confidence.
2024-04-08 Chinese
迈威生物自愿披露关于迈卫健？获得国家药品监督管理局批准上市的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a pharmaceutical product by the National Medical Products Administration (国家药品监督管理局). It details the drug's basic information, clinical study results, overseas commercialization agreements, and potential risks. The document is a formal public disclosure about a regulatory approval event and its implications for the company. It does not contain financial statements, earnings data, or detailed management discussion. It is not a report or presentation but an official announcement of a significant corporate event related to product approval. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2024-04-03 Chinese
迈威生物自愿披露关于9MW2821在第55届美国妇科肿瘤学会（SGO）年会以聚焦全体会议口头报告形式报告数据及其最新进展的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Maiwei Biotech about clinical trial data presented at the 55th Society of Gynecologic Oncology (SGO) annual meeting. It details clinical study results, drug development progress, and risk warnings related to the drug 9MW2821. The text is an announcement of clinical data presentation and progress, not a full financial or regulatory report. It does not contain financial statements, audit information, or detailed management discussion. It is not a report publication announcement since it provides substantive clinical data and study results rather than just announcing a report's availability. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about clinical progress and data disclosure that does not fit into other specific categories like earnings release or management report.
2024-03-17 Chinese
迈威生物自愿披露关于9MW2821获美国FDA快速通道认定的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the FDA Fast Track Designation for a drug candidate (9MW2821). It provides detailed information about the drug, clinical progress, epidemiology, impact on the company, and risk warnings. The document is relatively short (2391 characters) and is an announcement of a regulatory milestone rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management changes. It is not a report publication announcement since it does not mention the release or availability of a report. The content fits best under Regulatory Filings (RNS) as it is a regulatory announcement about a clinical development milestone and related company impact, which does not fit other more specific categories.
2024-02-25 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.